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In the early days of the HIV epidemic, it was observed that a minority of the infected patients did not progress to AIDS or death
and maintained stable CD4+ cell counts. As the technique for measuring viral load became available it was evident that some of
these nonprogressors in addition to preserved CD4+ cell counts had very low or even undetectable viral replication. They were
therefore termed controllers, while those with viral replication were termed long-term nonprogressors (LTNPs). Genetics and
virology play a role in nonprogression, but does not provide a full explanation. Therefore, host diﬀerences in the immunological
response have been proposed. Moreover, the immunological response can be divided into an immune homeostasis resistant to
HIV and an immune response leading to viral control. Thus, non-progression in LTNP and controllers may be due to diﬀerent
immunological mechanisms. Understanding the lack of disease progression and the diﬀerent interactions between HIV and the
immune system could ideally teach us how to develop a functional cure for HIV infection. Here we review immunological features
of controllers and LTNP, highlighting diﬀerences and clinical implications.
1.Introduction
Prior to the introduction of combination antiretroviral ther-
apy(cART)itwasobservedthataminority oftheindividuals
infected with Human Immunodeﬁciency Virus type 1 (HIV-
1, from now on referred to as HIV) did not progress to
Acquired Immunodeﬁciency Syndrome (AIDS) or death.
This minority maintained normal CD4+ cell counts in the
absence of treatment for several years—in some cases for
more than two decades (reviewed in [1]) and therefore the
terminology Long-Term Nonprogressors (LTNP) was pro-
posed. When the technique for measuring the viral load was
introduced it became evident that some of these patients,
who did not clinically progress, had low or even nonde-
tectable viral replication. This phenomenon leads to the
additive deﬁnition of the non progressor-phenotype referred
to as controllers due to their ability to control viral replica-
tion in the absence of cART. Today, non-progressors are a
collective name for controllers and LTNP who are clinically
similar. Except for certain demands for the duration of
the infection in LTNP, they are only to be diﬀerentiated
according to control or not of viral replication, respectively.
Understanding the mechanism for the lack of disease pro-
gression in controllers and LNTP could ideally teach us how
to develop a functional cure for HIV infection, and for this
reason these subpopulations of HIV-infected patients have
gained immense interest.
Non-progressors are described to diﬀer from progressors
in genetics, virology, and immunology. Genetically, certain
factors seem to predispose to non-progressions. Thus, it
has been shown that female gender, the presence of CCR5-
delta32 polymorphism, and HLA genes, in particular the
HLA B57 allele, are overrepresented among non-progressors
([2–9], reviewed in [10]). Virologically, a number of studies
have indeed shown that some non-progressors are infected
with less virulent strains of HIV resulting in a more benign
infection [11–14]. However, there are now several lines of
evidence that the majority of non-progressors are infected2 AIDS Research and Treatment
with replicant-competent virus [15–17]. One study has
shownthatCD4+cellsfromcontrollersarelesssusceptibleto
HIV compared to CD4+ cells from progressors and healthy
controls [18], while another study showed that CD4+ cells
from controllers were as susceptible or even more susceptible
to HIV entry and productive infection [19].
Thus, genes and viral factors play a role in non-pro-
gression, but these components do not provide a thorough
explanation. For this reason the immune system is to be con-
sidered a key element in non-progression. This is supported
by the recent demonstrations of better control of hepatitis C
virus(HCV)inHCV-infectedcontrollerscomparedtoHCV-
infected progressors [20, 21]. The immunological response
to HIV infection can be divided into (1) an immune home-
ostasis resistant to HIV in LTNP and (2) the immune-
mediated control of the virus in controllers. However,
despite these two possible interactions between HIV and the
immune system both resulting in preserved CD4+ cell
counts, few studies have compared immune homeostasis in
LTNP and controllers. The scope of this paper is to describe
immunology in non-progressing HIV infection and to
propose involved immunological mechanisms in LTNP and
controllers.
2. Deﬁnitions of Nonprogressors
It is well-established that LTNP and controllers are diﬀerent
subpopulations [22–25], supporting the idea that diﬀerent
immunological mechanisms are responsible for the pre-
served CD4+ cell counts. LTNP and controllers are described
as rare populations comprising few percentages of all HIV-
infected individuals, and with little overlap between them
[22–27], although the deﬁnition of the populations suﬀers
from lack of consensus in terminology and inclusion criteria,
impeding the comparison of ﬁndings.
Controllers can be further divided into elite controllers
(EC) and viremic controllers (VCs), most commonly with
HIV RNA <50 copies/mL and 50–2000 copies/mL, respec-
tively,althoughvariationswithhigherlevelsarefoundaswell
([25], reviewed in[27, 28]). This is in particular a problem
because LTNP can thereby be categorized as VC due to their
often relatively low viremia. In addition, a central problem
in deﬁning the non-progressor phenotype is a complete lack
of inclusion of the viral load, thereby including LTNP who
fulﬁll controller-criteria with low or undetectable viral loads.
Patientsneednotnecessarilybeinfectedforalongperiod
of time in order to be categorized as controllers. Thus, two
measurements of a low viral load during one year are some-
times used as suﬃcient, whereas others demand duration
of infection for several years. In contrast, LTNPs due to the
nature of the case deﬁnition have a long duration of infec-
tion,mostcommonlyaminimumof7–10years.Bothgroups
present with a CD4+ cell count within the normal range
(350–1600 cells/μL) [22, 23, 25, 29]. Due to the low preva-
lence of these non-progressors, it is tempting to relax the
inclusion criteria. However, clinical outcomes seem to
improve with the stringency of criteria, and it has been
demonstrated that the clinical outcome for patients infected
for 7 versus 10 years and with stable CD4+ cell counts
Table 1: Deﬁnitions of non-progressors.
EC VC LTNP
CD4+ cell count (cells/μL) >350 >350 >350
Viral load (copies/mL) <50 50–200 >2000
Duration of infection (years) ∗∗ >7
cART No No No
∗Duration of infection is not used in the deﬁnition of controllers in this
review.
is diﬀerent. Thus, a better survival among LTNP deﬁned
by 10 years of stable infection versus 7 years is reported
[25], suggesting that even 7 years of stable infection do not
distinguish properly between true LTNP and progressors.
In this paper, unless anything else mentioned, the term
“non-progressors” is used as a collective name for controllers
and LTNP, while the term “controllers” is used for VC and
EC. The LTNP term is only used when studied patients
had substantial viremia above 2000 copies/mL and had been
infected for a minimum of 7 years. Although 7 years may not
be enough to exclusively distinguish LTNP from progressors,
7 years are chosen as most studies have used this deﬁnition.
Thedurationofinfectionincontrollersisnotincludedinour
deﬁnitions as we consider viral control at any time point to
be a suﬃcient determinant for controller status (Table 1).
3.Immunology inNon-Progressors
The CD4+ cell count in a given patient at any time is the
result of production, destruction, and traﬃc between blood
and lymphatic tissue, and when the destruction exceeds the
production the CD4+ cell count decreases. Thus, LTNP and
controllers may have diﬀerences in production, destruction,
or distribution of CD4+ cells compared to progressors in
order to maintain a normal CD4+ cell count.
4. Production of Cells
4.1. Bone Marrow and Progenitor Cells. T cells mature in the
thymus, but they originate from hematopoietic progenitor
cells (HPCs) in the bone marrow (BM). Thus, a functional
BM is crucial for thymopoiesis. In the hope of developing a
cure for HIV infection HPC has been given greater attention,
even more so after the report on eradication of HIV by trans-
plantation of CCR5-deﬁcient HPC in the so-called Berlin
patient [30]. HIV inﬂuences BM and HPC, and impaired
hematopoiesis in HIV infection is well documented [31–34].
Furthermore, several studies have shown that some HPCs
express the HIV receptors CD4, CXCR4, and CCR5 making
them potentially susceptible to HIV infection (reviewed in
[35]). HIV infection of HPC has recently been suggested
[36],althoughthecomplexitiesofpurifyingandmaintaining
HPC in culture make it diﬃcult to determine if these HPCs
are actually infected, as signs of infection may be due to
contamination with other cell types or maturation of HPC
to monocytes during in vitro culture. However, HIV proteins
seemsuﬃcienttodisturbthehaematopoiesis[37].Neverthe-
less, in addition to T cells, natural killer cells and B cells,AIDS Research and Treatment 3
Table 2: Immunological distinctions between progressors and non-progressors.
Controller LTNP Progressor
Production of T cells Thymic output preserved Thymus output? Thymic output ↓
Haematopoiesis preserved Haematopoiesis? Haematopoiesis exhausted
IL-7/IL-7R IL-7 Normal IL-7 ↑ IL-7 ↑
IL-7R Normal IL-7R ↓ IL-7R ↓
Destruction of T cells
Immune activation ↑ Immune activation ↑↑ Immune activation ↑↑↑
Turnover/apoptosis ↑ Turnover/apoptosis? Turnover/apoptosis ↑↑
Microbial translocation ↑ ? Microbial translocation ↑↑↑Microbial translocation
Secondary lymphoid
tissue Preserved architecture ? Damaged architecture
Pro- and
anti-inﬂammatory cells
↓Tregs ? Tregs ↑↑Tregs
↑Th17 ↑Th17 ↓Th17
HIV-speciﬁc immune
response Strong ? Blunted
Viral reservoir Low ? High
↑/↓: Indicates slightly, ↑↑/↓↓:m o d e r a t e ,↑↑↑/↓↓↓: highly diﬀerent from HIV-negative individuals.
LTNP: long-term non-progressors, Tregs: regulatory T cells.
?: Indicates unknown.
including na¨ ıve B cells, seem to be depleted during HIV
infection [38]. HIV-associated lymphopenia may therefore
be explained by more upstream elements of lymphocyte
development than reduced thymic output.
Circulating HPCs have been found to decrease with dis-
ease progression and to be associated with CD4+ cell count
[39], supporting the idea of BM and HPC as being essential
in preservation of CD4+ cell count and suggesting preserved
haematopoiesis in non-progressors. The haematopoiesis has
only been assessed in a single study of elite controllers
(Table 2). This study included progressing as well as non-
progressing EC. Interestingly, the progressing EC showed
signs of exhausted lymphopoiesis compared the non-
progressing EC measured as CD34+ cells and lymphoid-
HPC [39]. This is supportive of a suﬃcient haematopoiesis
as a contributing factor to non-progression in controllers.
Also,itindicatesthattheviralreplicationitselfisnottheonly
reason for disease progression.
4.2. Thymus and Naive Cells. The CD4+ cell count is
maintained by proliferation of already existing CD4+ cells or
by de novo production in the thymus. Earlier, it was believed
that the thymus was only active in childhood and replaced
by fatty tissue with increasing age. It is now evident that the
thymus can also be active in adulthood, particularly during
circumstances with lymphopenia, as is the case with HIV
infection [40, 41]. Often thymic function is assessed as T-
cell receptor excision circles (TRECs) or as the naive CD4+
cell count. TRECs are stable circular DNA fragments that
are excised during the formation of TCR in the maturing T
cell in the thymus, and TRECs are not replicated during cell
division. Thus, the more immature CD4+ cells the higher
the TREC content. A large thymus on CT scans has been
associated with a higher CD4+ TREC frequency in HIV-
infected patients [42]. Thus, TRECs and naive cells are all
reasonable indirect measurements of thymic size and output.
HIV leads to a disruption in the number and function
of na¨ ıve CD4+ cells in blood as well as in lymphoid
tissue [43–45]. To our knowledge, no studies of na¨ ıve cells
have discriminated between controllers and LTNP. In non-
progressors, similar and lower numbers of na¨ ıve CD4+
cells have been found compared to progressors [8, 46,
47], suggesting that the level of na¨ ıve CD4+ cells itself is
not associated with non-progression (Table 2). In contrast,
increased expression of the na¨ ıve marker CCR7, higher levels
of central memory cells with preserved ability to secrete
interleukin 2 (IL-2), and a much higher thymic output as
deﬁned by TRECs in EC compared to progressors have been
reported [46, 48], supporting preserved thymic function
in non-progressors. The contribution of a well-functioning
thymopoiesis to non-progression is further supported by the
ﬁndings of strong correlations between TRECs and non-
progression in SIV-infected rhesus macaques [49]. Also,
normal levels of memory cells and preserved IL-2 secretion
capacities have been shown in non-progressing SIV-infected
rhesus macaques compared to progressors [50]. For this
reason,itseemsplausiblethatthethymicfunctionisbetterin
non-progressors compared to progressors, improving their
abilitytomaintainanormalCD4+cellcount.However,these
ﬁndings only explain the preserved CD4+ cell count in non-
progressors, not the viral control in controllers. In fact, the
high thymic output may indirectly be a consequence of and
not a reason for the low viral replication, since lower viral
replication does not lead to the exhaustion of lymphopoiesis
normally seen in progressors [39]. Thus, it would be of
great interest to compare the thymic output in LTNP and
progressorssincebothpopulationshaveviralreplication.Itis
tempting to assume that one of the main diﬀerences between
these progressors and LTNP is an extraordinary capacity to
produce cells. This is supported by ﬁndings of higher levels
of na¨ ıve cells in a study of slow-compared to fast progressors
based on the slope of their CD4+ cell loss, although this did4 AIDS Research and Treatment
not reach statistical signiﬁcance [51] .L i k e w i s e ,as t u d yo f
children with LTNP status displayed higher levels of na¨ ıve
cells compared to progressors and controls [52].
Thymic output is dramatically reduced with age, and
the na¨ ıve cells are increasingly generated from peripheral
proliferation(reviewedin [53]).Proliferationofcellsleadsto
a lower TREC count, and therefore na¨ ıve cells in older indi-
v i d u a l sh a v el o w e rT R E Cc o u n t s[ 54, 55]. Thus, the reported
loss of the non-progressor status in some individuals may be
due to increasing age and thereby decreased thymic output,
because the thymus is no longer able to meet the demands of
a high production of cells. This is supported by the ﬁndings
of an immune system in HIV-infected patients which is
comparable to much older healthy individuals [39]. Also,
high age is a predictor of poor immune reconstitution after
initiation of cART [56].
4.3. IL7. Production of CD4+cells is inﬂuenced by Inter-
leukin 7 (IL-7). IL-7 is crucial in the T-cell homeostasis, and
the IL-7 responsiveness is determined largely by the presence
or absence of the IL-7 receptor (IL-7R), which is present on
most mature T cells [57]. A negative correlation between
IL-7 and CD4+ cell count is described. Consequently, HIV-
infected progressors have high levels of IL-7 and reduced lev-
els of IL-7R compared to healthycontrols [58, 59], consistent
with the need for increased production of CD4+ cells and a
down-regulation of the receptor due to high plasma levels.
Thus, controllers would be expected to display a pattern of
IL-7/IL-7R closer to healthy controls than to progressors.
This is supported by ﬁndings of lower levels of IL7 in
controllers compared to controllers who lost their controller
status [60] and by ﬁndings of lower levels of IL-7R in
progressorscomparedtonon-progressors[47].Incontrast,it
would make sense that LTNPs display a pattern of IL-7/IL-7R
more like progressors than controllers, because the need for
CD4+ cell replenishment would be expected to depend on
the level of viral replication—infection and cell—turnover,
which is supported by ﬁndings from our own lab (unpub-
lished data) These results are compatible with a hypothesis
of low viral replication leading to a reduced number of new
CD4+cellsbecominginfected.Thereby,thelevelofIL-7does
not increase, and the IL-7R expression stays high. However,
further studies are warranted to clarify this.
5.Destruction ofCells
5.1. Immune Activation, Senescence, and Apoptosis. Immune
activation (IA) is a necessary and normal acute response
uponinfectionwithanypathogen,asaneﬀorttoavoidinfec-
tion. However, in HIV-infected individuals it is well estab-
lished that chronic IA is linked to and predictive of disease
progression, and IA has an additive or stronger prognostic
value than does CD4+ cell count or viral load alone [61–
68]. The inﬂuence of IA on disease progression can be partly
explained by elevated levels of senescent and apoptotic cells
as a consequence of IA, thereby leading to increased loss of
CD4+ cells.
Elevated markers of activation are to be found in most
cell compartments, but especially expression of the surface
markersCD38andHLA-DRonCD8+cellshaveproventobe
predictive of disease progression [64–68]. Thus, IA is a cen-
tral player in disease progression, as illustrated by the devel-
opment of pneumocystic pneumonia in rats solely as a con-
sequence of IA [69]. In light of this, it is obvious to assume
that IA in non-progressors is diﬀerent from progressors and
partly explains lack of progression. IA is one of the more
well-examined featuresin non-progressors and has in several
s t u d i e sb e e nf o u n dt ob el o w e ri nE Ca sw e l la sV Cc o m p a r e d
to progressors [70–74]. In support of the signiﬁcance of low
IA on lack of disease progression a study of EC revealed that
the individuals with the highest IA presented with the lowest
CD4+ cell counts [73]( Table 2). Also, the natural hosts of
simian immunodeﬁciency virus (SIV), sooty mangabeys and
African green monkeys, who do not progress despite a high
viral load (and thus can be seen as a simian pendant to
LTNP), do not show any signs of increased IA or T-cell
turnover [75, 76]. IA is inadequately examined in LTNP. One
study did not ﬁnd any diﬀerences in IA between EC and
LTNP, while they were both diﬀerent from progressors [77],
while another study did not ﬁnd any diﬀerences between
the three groups [78]. Interestingly, this latter study, one of
the only studies to have compared controllers and LTNP,
also evaluated the phenotypic and functional properties of
CD56/CD16 natural killer (NK) cells, a major component of
the innate immune system. Cytolytic activity against autolo-
gous CD4+ cells was found to be abrogated after treatment
with an antibody to NKp44L, the cellular ligand of the natu-
ralcytotoxicityreceptorNKp44,whichisspeciﬁcallyinduced
on CD4+ T cells during HIV-1 infection, in LTNP and HIV
progressors. In contrast, in HIV controllers and healthy
donors, NKp44L expression on CD4+ cells and autologous
NKlysiswerebothpoorlydetected[78].Thisisstronglysup-
portive of LTNP and controllers as being immunologically
diﬀerent.
Another component of the innate immune system that
may be involved in non-progression is the plasmacytoid
Dendritic Cells (pDCs). PDCs have been suggested as induc-
ers of IA and CD4+ cell apoptosis as they recognize HIV
single-stranded RNA (ssRNA) via Toll-like receptors (TLR)
resulting in interferon (INF) α production [79–82]. Further-
more,polymorphismsinTLR7andtheinterferonregulator7
of INFα may inﬂuence disease progression and the ability of
pDCs to produce INFα [83, 84]. In controllers, the number
a n df u n c t i o no fp D C sa r er e p o r t e dt ob ep r e s e r v e d[ 85].
In addition, pDCs from rhesus macaques produce large
amountsofINFαwhenstimulatedwithSIVorHIV,whilethe
natural hosts, sooty mangabeys, seem to have lower levels of
INFα [86]. Altogether, this suggests pDCs to induce IA, and
they may therefore be involved in non-progression of HIV
infection.
IA is accompanied by apoptosis and immunological
senescence, and HIV-infected patients present with elevated
levels of both features [87, 88]. Senescent cells in EC and
progressors have been examined in a single study, and com-
p a r a b l el e v e l sw e r ef o u n d[ 8]. In contrast, in a study of non-
progressors with unknown viral load the level of apoptosis
was found to be similar to healthy controls and lower than
in progressors [89], and others have reported lower levelsAIDS Research and Treatment 5
of apoptosis in VC compared to progressors [90], both sup-
porting the idea of a lower turnover as contributing to non-
progression. However, low turnover could also simply reﬂect
a lower IA. Contrary, another study found elevated levels of
apoptotic cells in non-progressors compared to progressors
[91], implying that a high turnover is beneﬁcial. This ﬁnding
makes sense, if we assume that activated cells are eliminated
by apoptosis. Then an increasing proportion of apoptotic
cells eliminate the harmful IA, thereby diminishing disease
progression. Either way, evidence is lacking, and whether a
high turnover of cells is contributing to non-progression is
still to be determined.
Thus, it seems reasonable to assume that the level of
IA is a determinant for how fast the turnover of T cells is,
thereby relating IA to exhaustion (Table 2). Indeed, it has
been proposed that IA leads to CD4+ cell depletion because
it erodes the na¨ ıve T-cell pool [92]. Still, the reason for the
strong predictive value of IA in HIV infection is uncertain,
but low IA found in controllers suggests that IA forms an
important role in lack of progression.
6. ImmuneRegulation: Pro-and
Anti-InﬂammatoryCells
The understanding of the immune system is constantly
changing as a consequence of rapidly expanding knowledge.
Recently, the discovery of T-cell subsets with pro- and anti-
inﬂammatory properties has altered our view on immunol-
ogy. Regulatory T cells (Tregs) are anti-inﬂammatory T cells,
while Th17 cells have proinﬂammatory properties. Tregs are
crucial in sustaining tolerance to self-antigens [93, 94]a n d
suppressing T-cell activation resulting in down-regulation
of immune activation, including reduction in anti-tumor
immunity, graft rejection, and graft versus host disease ([95],
reviewed in [96]). Finally, the role of Tregs in chronic
viral infections, including HIV, has gained considerable
interest due to their immunosuppressive capabilities. Thus,
intheory,TregscandownregulatethechronicIAseeninHIV
infection making Tregs a key element in the understanding
of the interaction between the host immune system and
HIV (reviewed in [97]). For this reason, Tregs have been
suggested as downregulators of the unbeneﬁcial unspeciﬁc
IA in HIV-infection, expecting high levels of Tregs as being
an advantage. However, levels of Tregs in HIV-infected,
untreated, progressing patients have been shown to be
elevated compared to healthy controls in a number of
studies ([98–100]r e v i e w e di n[ 101]). This suggests that high
levels of Tregs are actually harmful, possibly because they
downregulate beneﬁcial HIV-speciﬁc responses. In support
of this, the level of Tregs in controllers has been reported
to be lower compared to progressors, and closer to healthy
controls, although conﬂicting results have been reported as
well [70, 77, 102–106]. Furthermore, it has been shown that
the suppressive activity of Tregs in EC is preserved, while it
was found to be disrupted in progressors [105].Finally, Tregs
have been suggested to increase with age (reviewed in [107]),
possiblycontributingtothereportedlossofnon-progression
in some individuals. All together this is supportive of a
signiﬁcant inﬂuence of Tregs on non-progression.
However, like most other pieces in the puzzle of under-
standing the interaction of HIV and the immune system the
Treg element has proven to be more complex than expected.
Thus, Tregs are closely related to IL-17-producing Th17
cells. Tregs and Th17 cells share a reciprocal maturation
pathway and function together in opposing ways to control
the inﬂammatory response upon infection. While Tregs
inhibit autoimmunity, Th17 cells have been shown to play
a critical role in the induction of autoimmune tissue injury
and immune responses [108]. Th17 cells have been shown
to be rapidly depleted during acute SIV infection cells, and a
disturbed balance of Th17 cells and Tregs has been suggested
to be associated with subsequent high IA and disease pro-
gression([109,110],reviewedin[101,111]).Incontrollers,a
maintained balance between Tregs and Th17 cells is reported
[102]( r e v i e w e di n[ 112]), highlighting the signiﬁcance of a
well-regulated balance between Tregs and Th17 cells. Th17
cells and Tregs have primarily been examined in controllers.
However, one study of a group of non-progressors, where
mostparticipants met theLTNPcriteria,havefound elevated
levels of Th17 cells compared to progressors [113]. Thus, a
high level of Th17 cells may contribute to lack of progression
in controllers as well as in LTNP. However, HIV leads to
redistribution of CD4+ cells between blood and lymphatic
tissue (LT). Thus, it has been demonstrated that HIV binds
to resting CD4+ cells and upregulates L-selectin causing the
cells to home from the blood into lymph nodes (LNs) at
enhancedrates[114,115].Thishasledtothehomingtheory,
oﬀering an explanation for the loss of CD4+ cells due to cells
leaving the blood and entering the LT (reviewed in [116]).
Indeed, accumulation of Tregs has been found in secondary
lymphatic tissue (SLT) compared to peripheral blood in
untreated HIV-infected patients [117, 118], indicating that
the conclusion drawn from the reported ﬁndings of Tregs in
p e r i p h e r a lb l o o di st ob ec o n s i d e r e dw i t hc a u t i o n .
7.Secondary Lymphatic Tissueand
MicrobialTranslocation
CD4+ cell depletion occurs in the blood as well as in the
SLTofLNandgut-associatedlymphatictissue(GALT)where
the majority of the CD4+ cells reside. During primary HIV
infection a vast number of cells are depleted, reaching a loss
of more than 50% in LN as chronic infection is established
[119,120].IthasbeenproposedthatHIVdamagesthestruc-
tures in the LT, that help sustain the normal CD4+ cell popu-
lation replacing the functional space with collagen. Thus, the
greater the amount of the collagen deposition, the lower the
CD4+ cell count and the smaller the number of naive CD4+
cells [121]. Also, LN biopsies from HIV- and SIV-infected
individuals show breakdown of the lymph node architecture
and evidence of apoptosis [122]. In contrast, a preserved
lymph-node architecture was reported in the history of HIV
in non-progressors compared to progressors, indicating that
progressors host a preserved SLT [123]. GALT is the main
defence against infectious microorganisms in the gastroin-
testinal (GI) tract and consists largely of T cells. Importantly,
the main part of Th17 cells reside in the GALT [124]. Th17
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barrier by stimulating epithelial proliferation and inducing
a proinﬂammatory environment by recruiting neutrophils to
ﬁght microorganisms. Upon acute HIV infection follows a
signiﬁcant depletion of CD4+ cells in the GALT [125, 126].
The depletion is linked to a damage of the mucosal barrier
that may be due to an imbalance of Th17 cells as the massive
depletion of CD4+ cells during acute HIV and SIV infection
in particular includes Th17 cells [125, 126]. The damage
to the mucosal barrier results in microbial translocation
(MT)—a continuing leak of microbial remnants from the
GI tract that enters the systemic circulation. These microbial
products lead to immune activation [111, 127, 128], thereby
contributing to HIV progression. The data on mucosal
integrity and the inﬂuence of MT on immune activation
in non-progressors are limited. One study using a rhesus
macaque model has shown that spontaneous restoration of
mucosal CD4+ cells upon acute SIV infection is predictive
of non-progression [129]. Furthermore, EC and VC present
with similar preserved numbers of CD4+ cells in rectal
biopsies comparable to HIV-negative individuals, while the
number in progressors is reported to be diminished [130,
131]. However, the level of lipopolysaccharide (LPS) used as
a marker of MT is comparable in controllers and progressors
and elevated compared to HIV-negative individuals [73],
indicating that low chronic immune activation in non-
progressors might have eﬀect in the long-term despite the
appearance of the relatively intact mucosal barrier. Thus,
present data indicate that non-progressors are distinct from
progressors in several aspects of the integrity of the mucosal
barrier and MT, suggesting an important mechanism for
the capability of non-progressors to control immune activa-
tion and HIV infection. However, to determine the causal
relationship between MT and control of HIV infection
prospective studies are needed.
8.HIV-SpeciﬁcImmune Responses
HIV-speciﬁc CD8+ and CD4+ cells and neutralizing anti-
bodies are considered an important albeit most often insuf-
ﬁcient element in suppressing viral replication (reviewed in
[132, 133]). Some of the ﬁrst studies were made of HIV-
infected patients with primary infection. Here it was shown
that the level of HIV-speciﬁc CD8+ cells paralleled the
eﬃciency of control of primary viremia. Also, patients who
mounted strong gp160-speciﬁc CD8+ cell responses showed
rapid reduction of acute plasma viremia, while viremia in
patients with low virus speciﬁc CD8+ cell activity was poorly
controlled [134]. Another study showed that an absent HIV-
speciﬁc CD8+ cell response during primary HIV infection
wasassociatedwithprolongedsymptoms,persistentviremia,
and low CD4+ T-cell count [135]. Furthermore, it has been
shown that in vivo depletion of CD8+ cells eliminates the
ability to contain SIV replication [136]. For this reason an
HIV-speciﬁc CD8+ cell immune response is widely accepted
as a contributor to control of viral replication and lack of
progression in non-progressors, and this has been evaluated
in a number of studies. Thus, it has been shown that
non-progressors are able to maintain an established CD8+
cell precursor pool and present with a consistent highly
functional HIV-speciﬁc response, while this ability is lost in
progressors [137, 138]. Also, the capacity of virus-speciﬁc
CD8+cellstoproliferateinresponsetostimulationwithHIV
antigens is reported to be preserved only in non-progressors
[139]. This is in agreement with ﬁndings from a prospective
study of an increase in polyfunctionality in HIV-speciﬁc
CD8+ cell responses from EC, and a decrease in progressors
over time [140], and with ﬁndings of a stronger and broader
cytokine and chemokine response following HIV-speciﬁc
stimulation of PBMC from EC compared to progressors
[70, 77]. In addition, it has been reported that the inhibitory
immunoregulatory receptor CTLA-4 is selectively upregu-
lated in HIV-speciﬁc CD4+ cells in progressors compared to
non-progressors. CTLA-4 expression was also found to be
positive associated with disease progression and negatively
associated with the capacity of CD4+ cells to produce IL-
2i nr e s p o n s et ov i r a la n t i g e n[ 141]. Furthermore, it has
been shown that in non-progressors HIV-speciﬁc CD8+ T
cells eﬃciently eliminate primary autologous HIV-infected
CD4+ cells [142]. Additionally, it seems of importance if the
HIV-speciﬁc cells are activated or not, as it has been shown
that ECs possess lower levels of activated HIV-speciﬁc CD8+
cells and of recently divided HIV-speciﬁc CD4+ cells than
progressors [70]. Based on these data an ideal HIV vaccine
would induce strong HIV-speciﬁc immune responses and
minimize HIV-speciﬁc immune activation. Another goal of
vaccine development is induction of antibodies that neutral-
izeabroadrangeofHIVisolates.Althoughantibodies canbe
elicited by HIV infection, those that are broadly neutralizing
are undetectable in most individuals (reviewed in [143]).
The level and the breadth of neutralizing antibodies are
reported to correlate to viral load [144, 145], and the same
or lower levels of antibodies are reported in controllers
compared to progressors [144, 146]. Furthermore, one study
showed that no single anti-HIV antibody speciﬁcity was
a clear correlate of immunity in controllers [146]. This is
consistent with neutralizing antibodies as poor contributors
to non-progression. Contrary, antibodies directed against
autologous Env variants are reported to be present in
non-progressors [147], and eﬃcient elicitation of de novo
neutralizing antibodies has been shown in SIV controllers
[148].
Taken together these ﬁndings unanimously indicate that
a virus-speciﬁc response by CD8+ cells is a contributing
factor to non-progression, while the inﬂuence of virus-
speciﬁc CD4+ cells and neutralizing antibodies is more
unclear. Interestingly, similar preserved HIV-speciﬁc T-cell
responses have been demonstrated in a study of controllers
and LTNPs while responses were blunted in progressors
[149]. This indicates that HIV-speciﬁc responses are crucial
in sustaining non-progression, regardless the viral repli-
cation, consequently playing a role in non-progression in
c ontr ollersaswellasinL TNP .H o wev er ,thesebeneﬁcialHIV -
speciﬁc responses might be a part of the explanation of why
HIV is not being eradicated, even in controllers. Thus, it
has recently been shown that high HIV-speciﬁc responses are
associated with high levels of cell-associated HIV DNA levels
in controllers [150].AIDS Research and Treatment 7
9. Eradication,Latency,andReservoirs
Despite eﬀective cART complete eradication of HIV seems
unlikely, and complete eradication of HIV is so far only
obtained once in the Berlin-patient [30]. In general, low-
level HIV replication continues despite cART. This is in part
due to the capability of HIV to conceal itself and persist in
cellular reservoirs. Furthermore, a major impediment to the
eradicationofHIVislatentlyinfectedrestingCD4+cellsthat
are characterized by proviral DNA integration into the host
genome; particulary memory CD4+ cells have proven to be a
majorcellularr eserv oirforHIV[151].Themajoranatomical
site for HIV reservoir is SLT including GALT [152–154].
Thus, viral reservoirs are considered a major obstacle to
eradicate HIV and considered to be the reason for rebound
viraemia during cART interruptions. Notably, the concept of
a functional cure has emerged where lifelong control of viral
replication is obtained and disease progression is avoided
although provirus is detectable. This might be illustrated by
the viral control found EC.
Few studies have examined the capability of non pro-
gressors to eradicate or reduce HIV reservoirs and latency.
However, low proviral DNA in PBMC in EC compared to
patients on cART has been demonstrated [155, 156]. One
study even reported diﬀerences in the level of proviral loads
in EC compared to VC, implying that even low viral repli-
cation is of importance [17]. Furthermore, autologous viral
replication ex vivo was detected in only 2 out of 14 EC com-
paredto9outof10VCs,suggestingECstohaveadiminished
viral reservoir in peripheral CD4+ cell compartment [17].
Furthermore, impaired viral replication in the early phase of
H I Vs e e m st ob ep r e d i c t i v ef o rV C[ 157]. The anatomical
reservoir in GALT has been examined in a small study
revealing lower levels of HIV DNA in rectal tissue in LTNP
compared to progressors [158]. However, an SIV macaque
model demonstrated that colon mucosa and associated
lymph nodes are a major SIV reservoir even in controllers
[159].
Conclusively, non-progressors and especially EC seem
to have diminished cellular reservoirs, whereas the size of
the anatomical viral reservoirs in SLT is uncertain. However,
the described traﬃc of CD4+ cells between plasma and SLT
and the reduced microbial translocation indicate that non-
progressors harbor a lower viral reservoir in SLT than do
progressors. Understanding how ECs control and reduce
cellular reservoir might provide the basis to elucidate the
needs for a functional cure.
10. ClinicalImplications
A common feature in non-progressors is preserved immu-
nology. However, reports of loss of the non-progressor
status with declining CD4+ cell counts in LTNP have been
observed, and these patients may eventually require cART.
Likewise, a loss of viral control in controllers is reported.
Interestingly, progression and AIDS events in controllers
despite low or undetectable viral loads events are reported
as well [2, 8, 22, 29, 39, 48, 73, 160]. As a result of this, cART
has been suggested to controllers.
In EC viral replication cannot be measured in com-
mercial assays in EC. However, using ultrasensitive assays
HIV RNA can be detected in the majority of these patients
[161, 162], and it has been shown that loss of CD4+ cells
is more common among ECs with low level viremia [162].
Furthermore, low-level viremia is reported to be associated
withmeasurableTcelldysfunctioninEC[163].Finally,ishas
been shown that blips are associated with a nonfavourable
clinical outcome [26]. Taken together, this indicates that
even very low levels of viremia have clinical implications
and are involved in disease progression. This is supported by
ﬁndings of higher levels of immune activation in controllers
compared to patients on cART [73, 164]. Moreover, it
seems plausible that cART would normalize immunological
parameters in controllers. This is conﬁrmed by ﬁndings of
declining immune activation in EC and increasing CD4+
cell counts in EC as well as EC as due to cART initiation
[165, 166]. Thus, cART may be considered in progressing
controllers despite undetectable viral replication.
11. Conclusion andFutureDirections
Rare groups of HIV-infected patients that do not progress to
AIDS or death have been known since the beginning of the
HIV epidemic. Some of these non-progressors control viral
replication, that is, the controllers, while LTNP, have ongoing
viral replication. So far, it is not clear why these patients
do not progress, but immunological mechanisms have been
suggested.TheimmunologicalresponsetoHIVinfectioncan
be divided into an immune homeostasis resistant to HIV
and an immune response leading to viral control. This paper
has focused on immunology in non-progressors. We suggest
that two diﬀerent mechanisms are responsible for preserved
CD4+ cell counts in controllers and LTNP.
In summary, data unambiguously show that controllers
are immunologically diﬀerent from progressors in produc-
tion, destruction, and regulation of cells. Thus, controllers
have a preserved CD4+ cell production with a bone marrow
function, a lymphopoiesis, a thymic output, and an IL-
7/IL7-R balance resembling HIV-negative individuals. Fur-
thermore, controllers have lower destruction of CD4+ cells
as evidenced by lower microbial translocation, immune
activation, and apoptosis. Likewise, the balance between
T r e g sa n dT h 1 7c e l l si sl e s sd i s t u r b e da n dH I Vr e s e r v o i r s
seem to be lower compared to progressors. However, non-
progression and preserved CD4+ cells counts in controllers
may not be entirely surprising since they are characterized
by viral control and thus to be compared with HIV-infected
patients on treatment. Thus, preserved immune homeostasis
may be a reﬂection of rather than a reason for the viral
control. In contrast, high level of HIV-speciﬁc immune
response in controllers is probably a contributing factor to
non-progression in controllers.
The really intriguing question is how non-progression
occurs in LTNP where continuous viral replication is evident
and ought to result in destruction of CD4+ cells. Unfor-
tunately, the literature of LTNP is limited, often because
they are included in study populations of controllers as viral
load is not included in the deﬁnitions. An extraordinary8 AIDS Research and Treatment
ability to produce cells or a lower rate of destruction is
expected in these patients according to the preservation
of normal CD4+ cell counts. However, increased rate of
production has not been shown so far, and the ﬁnding of
similar levels of IL-7 between LTNP and progressors suggests
that a diﬀerent CD4+ production is not the explanation
for non-progression in LTNP. Likewise, evidence of reduced
turnover of cells in LTNP has not been found, and in general
LTNPs appear to have an immune system very much like
progressors.However,ﬁndingsofelevatedlevelsofTh17cells
have been reported, suggesting that the immune regulation
by pro- and anti-inﬂammatory cells is diﬀerent in LTNP
compared to progressors. Indeed, it would be interesting to
further evaluate immunological parameters, includingTh17
cells, Tregs, and microbial translocation in LTNP, ideally in
prospective studies in order to clarify cause and eﬀect. Also,
it would be of interest to elucidate immunological param-
eters in former LTNP who have lost their non-progressor
status.
Finally, due to distinct immunologically proﬁles in LTNP
and controllers, we suggest that a clear distinction between
patients with and without viral replication is made in future
studies in order to improve the possibility to understand
the diﬀerent mechanisms for non-progression in these
fascinating patients.
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